Multifaceted Nature of HuR in Atherosclerosis Development
- PMID: 38310400
- DOI: 10.2174/0109298673279032231214110313
Multifaceted Nature of HuR in Atherosclerosis Development
Abstract
HuR (Human antigen R) is an RNA binding protein (RBP) that specifically binds to certain RNA sequences, influencing post-transcriptional regulation. HuR is primarily involved in tumor regulation, as well as cell growth, proliferation, inflammation, and angiogenesis. HuR is implicated in endothelial activation, smooth muscle proliferation, inflammatory response, macrophage apoptosis, lipid regulation, and autophagy, playing a crucial regulatory role in atherosclerosis. Accumulating evidence suggests that HuR has dual roles in AS. On the one hand, HuR expedites the development of AS by facilitating endothelial activation, smooth muscle proliferation, and inflammation. On the contrary, it exerts beneficial effects by reducing macrophage apoptosis, regulating lipid efflux, and increasing autophagy. In this review, we aim to provide a comprehensive summary of the role of HuR in the development of AS by examining its involvement in cellular mechanisms, inflammation, autophagy, and apoptosis. Additionally, we discuss the mechanisms of drugs that target HuR, with the goal of offering new perspectives for the treatment of AS.
Keywords: 3‘ UTR; Atherosclerosis; embryonic lethal.; endothelial cells; human antigen R; nucleoplasmic translocation.
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Similar articles
-
HuR inhibition reduces post-ischemic cardiac remodeling by dampening myocyte-dependent inflammatory gene expression and the innate immune response.FASEB J. 2025 Mar 31;39(6):e70433. doi: 10.1096/fj.202400532RRR. FASEB J. 2025. PMID: 40085190 Free PMC article.
-
Targeting the HuR/E2F7 axis synergizes with bortezomib against multiple myeloma.Acta Pharmacol Sin. 2025 Aug;46(8):2296-2309. doi: 10.1038/s41401-025-01529-3. Epub 2025 Mar 25. Acta Pharmacol Sin. 2025. PMID: 40133626 Free PMC article.
-
RNA binding protein HuR regulated by OIP5-AS1 may be involved in maternal transcript degradation during the human maternal-to-zygotic transition.BMC Genomics. 2025 Jul 1;26(1):600. doi: 10.1186/s12864-025-11807-3. BMC Genomics. 2025. PMID: 40597633 Free PMC article.
-
Multiple functions of HuR in urinary tumors.J Cancer Res Clin Oncol. 2019 Jan;145(1):11-18. doi: 10.1007/s00432-018-2778-2. Epub 2018 Oct 28. J Cancer Res Clin Oncol. 2019. PMID: 30370480 Free PMC article. Review.
-
Vascular Smooth Muscle Cells: A Therapeutic Target in Atherosclerosis.Rev Cardiovasc Med. 2025 Jun 26;26(6):28240. doi: 10.31083/RCM28240. eCollection 2025 Jun. Rev Cardiovasc Med. 2025. PMID: 40630429 Free PMC article. Review.
Cited by
-
Involvement of Lipids and Lipid Mediators in Inflammation and Atherogenesis.Curr Med Chem. 2025;32(15):2971-2991. doi: 10.2174/0109298673303369240312092913. Curr Med Chem. 2025. PMID: 38504569 Review.
-
Multifaceted Human Antigen R (HuR): A Key Player in Liver Metabolism and MASLD.Livers. 2025 Sep;5(3):33. doi: 10.3390/livers5030033. Epub 2025 Jul 21. Livers. 2025. PMID: 40809813 Free PMC article.
References
-
- Stellos K.; Gatsiou A.; Stamatelopoulos K.; Perisic Matic L.; John D.; Lunella F.F.; Jaé N.; Rossbach O.; Amrhein C.; Sigala F.; Boon R.A.; Fürtig B.; Manavski Y.; You X.; Uchida S.; Keller T.; Boeckel J.N.; Franco-Cereceda A.; Maegdefessel L.; Chen W.; Schwalbe H.; Bindereif A.; Eriksson P.; Hedin U.; Zeiher A.M.; Dimmeler S.; Adenosine-to-inosine RNA editing controls cathepsin S expression in atherosclerosis by enabling HuR-mediated post-transcriptional regulation. Nat Med 2016,22(10),1140-1150 - DOI - PubMed
-
- Vo D.T.; Abdelmohsen K.; Martindale J.L.; Qiao M.; Tominaga K.; Burton T.L.; Gelfond J.A.L.; Brenner A.J.; Patel V.; Trageser D.; Scheffler B.; Gorospe M.; Penalva L.O.F.; The oncogenic RNA-binding protein Musashi1 is regulated by HuR via mRNA translation and stability in glioblastoma cells. Mol Cancer Res 2012,10(1),143-155 - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- 81670429, 91839103/National Natural Science Foundation of China
- 2018WK4031/International Joint Laboratory for Arteriosclerotic Disease Research of Hunan Province
- 2020SK2105/Special Funding for Construction of Innovative Provinces in Hunan Province
- CX20221022/Postgraduate Scientific Research Innovation Project of Hunan Province
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous